| Symbol | SCNI |
|---|---|
| Name | SCINAI IMMUNOTHERAPEUTICS LTD. |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | JERUSALEM BIOPARK, 2ND FLOOR,HADASSAH EIN KEREM CAMPUS, JERUSALEM, Israel |
| Telephone | +972 89302529 |
| Fax | — |
| — | |
| Website | https://www.scinai.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001611747 |
| Description | BiondVax Pharmaceuticals Ltd is engaged in the healthcare sector. Its main activity is the commercialization and manufacturing of flu vaccine. Its product is designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains. The company recently concluded two Phase I/II trials in which the multimeric-001 universal flu vaccine was shown to be safe and immunogenic. Additional info from NASDAQ: |
Director GERMAIN MARK 🟢 acquired 120.0M shares of Scinai Immunotherapeutics Ltd. (SCNI) Transaction Date: Jun 16, 2026 | Filing ID: 003261
Read moreDirector Reichman Amir 🟢 acquired 400.0M shares of Scinai Immunotherapeutics Ltd. (SCNI) Transaction Date: Jun 16, 2026 | Filing ID: 003259
Read moreScinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
Read moreNew Form 424B3 - Scinai Immunotherapeutics Ltd. <b>Filed:</b> 2026-05-19 <b>AccNo:</b> 0001213900-26-058989 <b>Size:</b> 346 KB
Read moreScinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe
Read moreNew Form F-3 - Scinai Immunotherapeutics Ltd. <b>Filed:</b> 2026-05-08 <b>AccNo:</b> 0001213900-26-053855 <b>Size:</b> 921 KB
Read moreScinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities
Read moreScinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration
Read moreNew Form 20-F - Scinai Immunotherapeutics Ltd. <b>Filed:</b> 2026-04-01 <b>AccNo:</b> 0001213900-26-038011 <b>Size:</b> 12 MB
Read more